Proton pump inhibitor and histamine‐2 receptor antagonist use and risk of liver cancer in two population‐based studies

Alimentary Pharmacology & Therapeutics

Fecha de publicación: 9 May 2018

DOI: https://doi.org/10.1111/apt.14796

Autores: K. T. Tran, Ú. C. McMenamin, B. Hicks, P. Murchie, A. P. Thrift, H. G. Coleman, L. Iversen, B. T. Johnston, A. J. Lee, C. R. Cardwell

Background: Proton pump inhibitors (PPIs) and histamine‐2 receptor antagonists (H2RAs) are commonly used. PPIs have been shown to promote liver cancer in rats; however, only one study has examined the association in humans.